Sino-American biopharma Ascentage Pharma (HK: 6855) has announced that olverembatinib has been granted Breakthrough Therapy designation (BTD) by China’s Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA), alongside low-intensity chemotherapy, for first-line treatment of newly-diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).
This marks the third BTD for olverembatinib in China, a third-generation BCR-ABL tyrosine kinase inhibitor (TKI).
The first BTD was granted in March 2021 for the treatment of patients with chronic-phase chronic myeloid leukemia resistant and/or intolerant to first- and second-generation tyrosine kinase inhibitors, while the second was awarded in June 2023, for the treatment of patients with succinate dehydrogenase-deficient gastrointestinal stromal tumor who had received first-line treatment.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze